Financial insights of BIO

MyFinsight

For the quarter ending 2026-03-31, BIO made $592,100K in revenue. -$527,100K in net income. Net profit margin of -89.02%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net sales	592,100	693,200	653,000	651,600
Cost of goods sold	282,700	348,000	309,600	306,300
Gross profit	309,400	345,200	343,400	345,300
Selling, general and administrative expense	212,400	221,000	206,800	207,700
Research and development expense	62,900	70,300	71,300	60,500
Impairment of purchased intangibles and related items, net	-	172,800	-	-
Segment profit (gain)	34,100	-118,900	65,300	77,100
Interest expense	12,300	12,100	12,300	12,600
Foreign exchange (gains) losses, net	2,400	2,100	2,900	-1,100
(gains) losses from change in fair market value of equity securities and loan receivable	-	1,029,500	-	-
Marketable securities, unrealized (gain) loss	-738,200	-	-495,300	334,400
Other nonoperating income (expense)	24,200	28,600	8,300	16,200
Income (loss) from continuing operations before income taxes, noncontrolling interest	-689,800	929,200	-431,100	414,000
(provision) benefit for income taxes	-162,700	209,200	-89,200	96,200
Net income attributable to bio-rad	-527,100	720,000	-341,900	317,800

Basic EPS	-19.55	26.704	-12.7	11.67
Diluted EPS	-19.55	26.649	-12.7	11.67
Basic Average Shares	26,958,000	26,962,000	26,923,000	27,226,000
Diluted Average Shares	26,958,000	27,018,000	26,923,000	27,228,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.